

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 3, 2016

Rennova Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-35141
(Commission File Number)

68-0370244
(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida
(Address of Principal Executive Offices)

33401
(Zip Code)

(561) 855-1626
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

Attached to this report as Exhibit 99.1 is a presentation that Rennova Health, Inc. (the “Company”) will present at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC at the New York Palace Hotel, New York, New York on May 5, 2016.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, and any information presented at the conference, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)

| Exhibit No. | Exhibit Description |
|--------------------|----------------------------|
| 99.1 | Presentation slides. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 3, 2016

RENNOVA HEALTH, INC.

/s/ Seamus Lagan

Seamus Lagan

Chief Executive Officer

(principal executive officer)

EXHIBIT INDEX

| Exhibit No. | Exhibit Description |
|--------------------|----------------------------|
| 99.1 | Presentation slides. |

The background of the slide features a stylized DNA double helix structure. The left side of the helix is rendered in shades of orange and yellow, while the right side is in shades of blue and teal. The helix is set against a light blue background with faint, semi-transparent data charts and graphs, suggesting a focus on technology and healthcare data.

RennovaHealth

Solutions Driven By Innovation

Nasdaq: RNVA

Diagnostics and supportive software
solutions to healthcare providers.

May 2nd 2016

Forward-looking Statements and Non-GAAP Information


This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.

Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 13 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

Healthcare is being transformed



We have the technology



We have the science



We have the expertise



We are Rennova Health

Key Investment Highlights

- Five-year history of operations with multiple significant milestones
- Substantial and profitable revenues from our core lab testing business
- We operate in a very sizable and well established market place
- Focused strategic growth plan based off a solid foundation
 - We have a capable, experienced management team (200 employees)
 - Multiple laboratories in place with potential for additional tests
 - Value added products launched in 4Q 2015 to drive further growth
 - EHR & Practice Management product for Substance Abuse sector
 - Medical Billing
 - We have significant opportunity for growth of core business revenues; >90% of current revenues derived from diagnostics
 - We have secured in-network contracts with a number of payers nation wide
 - Supportive software solutions provide additional revenue opportunity and a more sustainable relationship with our customers


Renova has positioned itself to maintain a sustainable long term relationship with medical providers by providing a number of essential products and services, creating efficiencies for the provider and benefiting from additional revenue for the provision of these services and products

Rennova Health, Inc. offers a single source solution for Medical Providers

- The diagnostics sector has changed dramatically in the last few years
- Paper records and faxes meant different vendors to a medical provider could function side by side without communication
- Electronic platforms and integration have created a need for providers of solutions to communicate, efficiently, accurately, automatically and fast
- Medical providers need more than just diagnostics; They need an increasing number of integrated and interoperable solutions to enable their business to function
- Our core business is diagnostics:
 - Historically >95% of our revenue is from diagnostics
 - The focus on diagnostics combined with supportive software solutions means that is now changing
- Compliance needs have increased with an ever more demanding regulatory and payer environment

Rennova Health, Inc. offers a single source solution for Medical Providers

Our core business is diagnostics:
>90% of our revenue currently comes from diagnostics



2015 Accomplishments

Top three accomplishments:

Completed Lab Development



Supportive Software Development



Merger & Nasdaq listing



Launched in 4th quarter 2015

- Medical Mime EHR product designed specifically for substance abuse treatment sector
- Billing services for the substance abuse treatment sector
- CollabRx for cancer diagnostics and decision support
- Rebranded the combined entity after the merger to Rennova




Management

- **Seamus Lagan** **CEO**
20 years experience in the restructuring, development and management of startup and small companies
- **Jason Adams** **CFO**
CFO in behavioral health sector and Senior Financial Management of public companies
- **Victoria Nemerson, Esq.** **Corporate Counsel**
25 years experience as a trial and defense attorney in the healthcare sector
- **Steven Burdelski** **Chief Compliance Officer**
25 years with the FBI with responsibility for corporate and legal compliance to improve performance
- **Jack Seeley** **CEO, Marketing & Sales**
14 years experience in toxicology and Former VP for Solstas Lab Partners (now Quest Diagnostics)
- **Al Lechner** **EVP of Sales, Health Technology Solutions**
30 years with GE Healthcare. Responsible for healthcare technology & software sales.
- **Sebastien Sainsbury** **Investor & Public Relations**
Banking and wealth management and 10 years on the Board of AIG International
- **Tiffany Vandemark** **EVP, Marketing**
18 years in marketing. Oversaw the launch and first four years of Chobani (Greek yogurt)

Board of Directors

- **Thomas Mika** **Chairman of Rennova, CEO of CollabRx (subsidiary)**
10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard
- **Seamus Lagan** **CEO**
20 years experience in the restructuring, development and management of startup and small companies
Founder, investor and shareholder
- **Christopher Diamantis** **Director**
Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm.
- **Michael Goldberg** **Director**
16 years as CEO of an AMEX-listed healthcare company that acquired 23 labs and 2 hospitals under his tenure
- **Dr. Paul Billings** **Director**
A nationally recognized expert on genomic and precision medicine. Has served as Chief Medical Officer or Director of some of the nation's largest health care companies
- **Benjamin Frank** **Director**
Retired lawyer and businessman who served as Chairman of the Board of the Healthcare District of Palm Beach County
- **Robert Lee** **Director**
16 years as a Managing Director of Morgan Stanley Dean Witter and Managing Director of the M&A group at Morgan Stanley, where he worked closely with financial sponsors. Chairman of numerous audit committees

History in Numbers



Reconciliation of Adjusted Measures to GAAP displayed on page 13

Capitalization at April 15, 2016

| | |
|--|-------------------|
| Common Shares Outstanding | 14,782,557 |
| Dilutive Potential Shares: | |
| Stock Options @ WAVG \$6.41 | 1,822,675 |
| Warrants @ WAVG \$1.83 | 6,898,560 |
| Convertible Debt | 1,074,402 |
| Convertible Preferred Stock | 11,540,397 |
| <u>Total Dilutive Potential</u> | <u>21,336,034</u> |
| | |
| <u>Fully Diluted Common Shares Outstanding</u> | <u>36,118,591</u> |

Select Income Statement Items

Reconciliation of GAAP to Adjusted Measures

| <i>(in thousands)</i> | 2011 | 2012 | 2013 | 2014 | 2015 |
|--|----------|-----------|-----------|-----------|-------------|
| GAAP Net Revenue | \$ 3,993 | \$ 21,076 | \$ 41,889 | \$ 57,928 | \$ 18,393 |
| Reserve for Aged Accounts Receivable | - | - | - | 1,501 | 19,494 |
| Adjusted Revenues | \$ 3,993 | \$ 21,076 | \$ 41,889 | \$ 59,429 | \$ 37,887 |
| GAAP Pretax Income | \$ 415 | \$ 3,228 | \$ 13,829 | \$ 15,382 | \$ (43,759) |
| Depreciation and Amortization | 18 | 66 | 408 | 1,500 | 2,750 |
| Interest Expense | 175 | 654 | 475 | 514 | 2,690 |
| Impairment of Goodwill and Intangibles | - | - | - | - | 18,411 |
| Stock Compensation Expense | 13 | 235 | 63 | 852 | 3,628 |
| Reserve for Aged Accounts Receivable | - | - | - | 1,501 | 19,494 |
| Adjusted EBITDA | \$ 621 | \$ 4,183 | \$ 14,775 | \$ 19,749 | \$ 3,214 |
| Depreciation and Amortization | (18) | (66) | (408) | (1,500) | (2,750) |
| Cash Interest Expense | (175) | (409) | (242) | (511) | (1,164) |
| Other Income | (19) | 352 | (196) | 241 | 3,164 |
| Provision for Income Taxes at Standard 38.8% | (159) | (1,575) | (5,404) | (6,976) | (956) |
| Adjusted Net Income | \$ 250 | \$ 2,485 | \$ 8,525 | \$ 11,003 | \$ 1,508 |

Our Target Markets

Drug and Alcohol Rehabilitation

- Total Market Size – estimated at \$35 Billion*
- Large and growing number of facilities in a fragmented market
- Between 14,500 to 16,700 outpatient clinics*

Market growth from high demand:

- Over 23 million Americans are addicted to alcohol and other drugs**
- The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million***
- 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****

Pain Management Sector

- Total Market Size – estimated at \$2-\$4 billion*****
- Large and growing number of clinics in a fragmented market
- Private clinics in the U.S. estimated between 1,500 to 2,500
- More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication

Market growth from high demand:

- Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population***** Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life*****
- Between 5 to 8 million people use opioids for long-term pain management
- In 2012, U.S. providers wrote 259 million prescriptions for opioid painkillers*****

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services

- Efficiency
- Cost
- Revenue cycle management

Sources:

*IBIS World.

**The National Council on Alcoholism and Drug Dependency.

***SAMHSA.

****National Association of Alcoholism and Drug Abuse Counselors


*****The U.S. Addiction Rehab Market, Bharat Publication.

*****JAH.

*****CDC and Pain Physician Publication.



RENNOVA HEALTH LICENSING MAP AS OF APRIL 29, 2016



Our Payers

- **Initiated Medicaid Licensing & Third Party Payer initiative in December 2015**
 - Applied for Medicaid Licenses in 31 States
 - As of April 29, 2016 possess Medicaid Licenses in 16 States
- **Current Third Party Insurance Payer Contracts**
 - Blue Shield of California
 - Coventry (National Contract)
 - Corvel
 - Multiplan
 - PrimeHealth
 - FedMed
 - HealthSmart
 - America's Choice Provider Network
 - Tricare – South (Humana Military)



Strategy



The Long Term Strategy

Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders

How?

Build from a toxicology-focused company to:

1. A significant and diverse diagnostics business
2. Offering supportive software solutions that add value by generating sustainable customer relationships and revenue
3. Exploring and developing new opportunities to improve provider and patient experiences and outcomes.

Remain proactive to the needs of patients and medical providers.

2016 Goals

- **Strengthen core diagnostic business**
 - Capitalize on recent disruption in toxicology sector
 - Increase Clinical testing
 - Launch Pharmacogenomics testing
 - Launch DTC (direct to consumer) testing – StableSpot™ initial ambition, testosterone
- **Accelerate growth and/or launch:**
 - HTS supportive software product sales (EHR in Rehab sector)
 - Medical Billing services
 - Interpretation and decision support in cancer diagnostics



Clinical testing with advanced analyzers



Online Training Program Launch to deliver increased sales

Program Objectives:

- Ensure consistency in messaging and information
- Provide effective and easy to use platform
- Make information accessible anytime and from anywhere
- Enable opportunity for monitoring and assessment



**Initially for sales reps, but to be expanded over time for all employees.
Goal is 100% training compliance.**


Opportunities in the Pipeline

Epinox Diagnostics



**Diabetes and Rapid
diagnostic tests for providers
& consumers**

Genomas



**Genomics based
diagnostics - drug
management solution**

Key Investment Highlights

- Five-year history of operations with multiple significant milestones
- Substantial and profitable revenues from our core lab testing business
- We operate in a very sizable and well established market place
- Focused strategic growth plan based off a solid foundation
 - We have a capable, experienced management team (200 employees)
 - Multiple laboratories in place with potential for additional tests
 - Value added products launched in 4Q 2015 to drive further growth
 - EHR & Practice Management product for Substance Abuse sector
 - Medical Billing
 - We have significant opportunity for growth of core business revenues; >90% of current revenues derived from diagnostics
 - We have secured in-network contracts with a number of payers nation wide
 - Supportive software solutions provide additional revenue opportunity and a more sustainable relationship with our customers

Renova has positioned itself to maintain a sustainable long term relationship with medical providers by providing a number of essential products and services, creating efficiencies for the provider and benefiting from additional revenue for the provision of these services and products

400 South Australian Avenue
8th Floor
West Palm Beach, FL 33401
Phone: 844-RENNOVA
Email: info@rennovahealth.com

Q & A